A novel clinical laboratory indicator for measuring hematological toxicity prior to radioimmunotherapy

摘要

New clinical parameters are reported which may serve as predictors of the hematological toxicity associated with therapeutic radiolabeled antibodies, particularly those antibodies which target lymphoma cells which have a tendency to localize to the bone marrow.